2023
Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies
Thomas A, Gitto M, Shah S, Saito Y, Tirziu D, Chieffo A, Stefanini G, Lansky A. Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100607. PMID: 39130709, PMCID: PMC11307978, DOI: 10.1016/j.jscai.2023.100607.Peer-Reviewed Original ResearchDual antiplatelet therapyAntiplatelet regimensPatient-specific risk profileShorter DAPT durationDuration of therapyPercutaneous coronary interventionDAPT strategyIschemic riskAntiplatelet therapyDAPT durationAntiplatelet strategiesCoronary interventionOngoing trialsMajor trialsRecent trialsPractice guidelinesFuture therapiesRisk profileTherapyStent technologyTrialsRegimensNumber of trialsSignificant reductionSignificant changes
2022
Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy
Erdogan E, Bajaj R, Lansky A, Mathur A, Baumbach A, Bourantas C. Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy. Journal Of The American Heart Association 2022, 11: e026492. PMID: 36326067, PMCID: PMC9750080, DOI: 10.1161/jaha.122.026492.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary interventionStent failureStent restenosisStent thrombosisSecond-generation drug-eluting stentsConventional percutaneous coronary interventionHigh-risk patientsBetter clinical outcomesLong-term outcomesDrug-eluting stentsCumulative incidenceClinical outcomesWorse prognosisProcedural resultsComplex anatomyEndovascular devicesRestenosisTherapyStent technologyDrug kineticsIntravascular imagingTreatment planningNeointima tissueThrombosisTCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial
Kelbæk H, Lansky A, Xu B, Baumbach A, van Royen N, Knaapen P, Johnson T, Smits P, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Wijns W. TCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial. Journal Of The American College Of Cardiology 2022, 80: b66. DOI: 10.1016/j.jacc.2022.08.193.Peer-Reviewed Original Research
2017
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials
Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal 2017, 39: 1687-1697. PMID: 28171522, PMCID: PMC6251670, DOI: 10.1093/eurheartj/ehx037.Peer-Reviewed Original ResearchConceptsCardiovascular proceduresClinical trialsNeurological endpointsAcademic Research ConsortiumBenefit-risk assessmentAdjunctive pharmacologyNeurological complicationsNeurological outcomePreventive therapyClinical effectsNeurovascular injuryNeurological injuryNeurological riskEndpoint definitionsCardiovascular interventionsAscertainment methodsTherapyInjuryResearch ConsortiumRiskTrialsEndpointInherent risksSuch proceduresComplicationsProposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials An Academic Research Consortium Initiative
Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials An Academic Research Consortium Initiative. Journal Of The American College Of Cardiology 2017, 69: 679-691. PMID: 28183511, DOI: 10.1016/j.jacc.2016.11.045.Peer-Reviewed Original ResearchConceptsCardiovascular proceduresClinical trialsNeurological endpointsAcademic Research ConsortiumBenefit-risk assessmentAdjunctive pharmacologyNeurological complicationsNeurological outcomePreventive therapyClinical effectsNeurovascular injuryNeurological injuryNeurological riskEndpoint definitionsCardiovascular interventionsAscertainment methodsTherapyInjuryResearch ConsortiumRiskTrialsEndpointInherent risksSuch proceduresComplications
2016
Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction
Ng VG, Lansky AJ. Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics 2016, 5: 523-532. PMID: 28582000, DOI: 10.1016/j.iccl.2016.06.014.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMyocardial infarctionWorse outcomesOutcomes of womenCoronary artery diseaseCause of deathTreatment of womenReperfusion therapyAggressive treatmentArtery diseaseLate therapyTreatment optionsDisease presentationOutcome disparitiesPlaque developmentInfarctionTherapyWomenYoung menOutcomesMenTreatmentPathophysiologyDisease
2015
Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original Research
2013
Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome
Meier P, Fröhlich GM, Meller S, De Palma R, Lansky AJ. Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. Expert Review Of Cardiovascular Therapy 2013, 11: 437-445. PMID: 23570357, DOI: 10.1586/erc.13.23.Peer-Reviewed Original ResearchConceptsSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionAcute coronary syndromeCoronary syndromeMyocardial infarctionLong-term mortalityBest treatment strategyOptimal time pointNSTEACS patientsTerm mortalityCoronary angiographyOptimal therapyPoor prognosisTreatment strategiesInvasive therapyHigh mortalityOlder agePatientsTime pointsMortalityNSTEACSInfarctionSyndromeTherapyAngiography
2012
Interventions for ST Elevation Myocardial Infarction in Women
Ng VG, Lansky AJ. Interventions for ST Elevation Myocardial Infarction in Women. Interventional Cardiology Clinics 2012, 1: 453-465. PMID: 28581963, DOI: 10.1016/j.iccl.2012.06.004.Peer-Reviewed Original ResearchST-segment elevation myocardial infarctionElevation myocardial infarctionReperfusion therapyMyocardial infarctionST-elevation myocardial infarctionOutcomes of patientsMinority of patientsOutcomes of womenCoronary revascularization techniquesCause of deathRevascularization techniquesSupportive careTreatment optionsCardiovascular diseaseEquivalent outcomesTherapyWomenMultiple studiesOutcomesInfarctionPatientsMenThrombolyticsDiseaseTrials
2011
Novel QCA methodologies and angiographic scores
Ng VG, Lansky AJ. Novel QCA methodologies and angiographic scores. The International Journal Of Cardiovascular Imaging 2011, 27: 157-165. PMID: 21337026, DOI: 10.1007/s10554-010-9787-9.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary artery diseaseCoronary angiography techniquesMultiple scoring systemsCoronary interventionArtery diseaseClinical factorsCoronary angiographyAngiographic scoreInterventional treatmentPatient riskGold standard methodScoring systemQCA dataAngiography techniquesVessel analysisAccurate assessmentAngiographyTherapy
2010
COMPLIANCE WITH DUAL ANTIPLATELET THERAPY AND SUBSEQUENT ADVERSE EVENTS IN PATIENTS WITH STEMI UNDERGOING STENT IMPLANTATION: ANALYSIS FROM THE HORIZONS-AMI TRIAL
Mehran R, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Caixeta A, Haratani N, Dangas G, Lansky A, Stone G. COMPLIANCE WITH DUAL ANTIPLATELET THERAPY AND SUBSEQUENT ADVERSE EVENTS IN PATIENTS WITH STEMI UNDERGOING STENT IMPLANTATION: ANALYSIS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2010, 55: a185.e1728. DOI: 10.1016/s0735-1097(10)61729-9.Peer-Reviewed Original Research
2005
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women
Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. Circulation 2005, 111: 940-953. PMID: 15687113, DOI: 10.1161/01.cir.0000155337.50423.c9.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary interventionAdjunctive pharmacotherapyHigh-risk acute coronary syndromesContemporary interventional therapyNonfatal ischemic complicationsAcute coronary syndromeAcute myocardial infarctionSex-specific dataCoronary syndromeIschemic complicationsMyocardial infarctionInterventional therapyWomenPharmacotherapyInterventionComplicationsInfarctionSyndromeTherapy
2003
Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III)
Limpijankit T, Mehran R, Mintz GS, Dangas G, Lansky AJ, Kao J, Ashby DT, Moussa I, Stone GW, Moses JW, Leon MB, Teirstein PS. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). The American Journal Of Cardiology 2003, 92: 315-318. PMID: 12888143, DOI: 10.1016/s0002-9149(03)00636-2.Peer-Reviewed Original ResearchConceptsAdverse eventsCoronary Artery Bypass GraftingTotal adverse eventsArtery Bypass GraftingCoronary artery bypassFirst-line therapyPercutaneous coronary interventionLong-term outcomesBrachytherapy failureArtery bypassBypass GraftingVessel revascularizationCoronary interventionIndependent predictorsMyocardial infarctionRadiation failureStent restenosisLate thrombosisPatientsTherapyBrachytherapyRevascularizationInfarctionThrombosisFailure
2002
Fate of nonflow-limiting dissections after treatment with iridium-192 therapy: results from the GAMMA I and II trials
Shirai K, Lansky A, Costantini-Ortiz C, Corral M, Dave N, Dieter L, Berger P, Desai K, Leon M. Fate of nonflow-limiting dissections after treatment with iridium-192 therapy: results from the GAMMA I and II trials. Journal Of The American College Of Cardiology 2002, 39: 14. DOI: 10.1016/s0735-1097(02)80056-0.Peer-Reviewed Original ResearchProlonged antiplatelet therapy and reduced stenting eliminates late thrombosis after radiation: the SCRIPPS III trial
Teirstein P, Moses J, Leon M, Casterella P, Reilly J, Glap H, Jani S, Balter S, Tripuraneni P, Lansky A, Negoita M, Mehran R. Prolonged antiplatelet therapy and reduced stenting eliminates late thrombosis after radiation: the SCRIPPS III trial. Journal Of The American College Of Cardiology 2002, 39: 65. DOI: 10.1016/s0735-1097(02)80281-9.Peer-Reviewed Original Research
2001
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting
Dangas G, Mehran R, Abizaid A, Curry B, Lansky A, Kent K, Pichard A, Satler L, Paliou M, Stone G, Leon M. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. The American Journal Of Cardiology 2001, 87: 470-472. PMID: 11179539, DOI: 10.1016/s0002-9149(00)01408-9.Peer-Reviewed Original Research
1998
Lipid-Lowering Therapy After Coronary Revascularization: The Interventional Cardiologist’s Perspective 11This work was supported by the Cardiology Research Foundation, Washington, DC.
Lansky A, Popma J, Mintz G, Laird J, Saucedo J, Leon M. Lipid-Lowering Therapy After Coronary Revascularization: The Interventional Cardiologist’s Perspective 11This work was supported by the Cardiology Research Foundation, Washington, DC. The American Journal Of Cardiology 1998, 81: 55e-62e. PMID: 9551596, DOI: 10.1016/s0002-9149(98)00199-4.Peer-Reviewed Original ResearchConceptsCoronary eventsCoronary interventionCholesterol levelsAggressive lipid-lowering therapyCardiology Research FoundationLipid-lowering therapyTreatment of stenosisPatients' cholesterol levelsLipid-laden plaqueCoronary revascularizationCoronary atherosclerosisUnderlying diseaseRevascularization proceduresAtherosclerotic progressionCardiologist's practiceAdvanced lesionsCholesterol reductionPlaque accumulationIntravascular ultrasoundOwn carePatientsTherapyInterventionRevascularizationAtherectomy
1996
Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy
Popma J, Lansky A, Ito S, Mintz G, Leon M. Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Progress In Cardiovascular Diseases 1996, 39: 111-128. PMID: 8841006, DOI: 10.1016/s0033-0620(96)80021-1.Peer-Reviewed Original ResearchConceptsBalloon angioplastyIntravascular ultrasoundSaphenous vein graft diseaseClinical useLate clinical benefitNative coronary arteriesVein graft diseaseStent designCurrent antiplateletAnticoagulation therapyAntithrombotic therapyGraft diseaseAdjunct therapyClinical benefitCoronary arteryStent placementDiffuse diseaseStent useBifurcation stenosisTherapySmall vesselsAngioplastyComplicationsNumber of studiesDisease